| 000 | 01801 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250513204217.0 | ||
| 264 | 0 | _c20000427 | |
| 008 | 200004s 0 0 eng d | ||
| 022 | _a0198-8859 | ||
| 024 | 7 |
_a10.1016/s0198-8859(99)00143-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBarta, A | |
| 245 | 0 | 0 |
_aImmunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. _h[electronic resource] |
| 260 |
_bHuman immunology _cFeb 2000 |
||
| 300 |
_a101-10 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents, Alkylating _xpharmacology |
| 650 | 0 | 4 |
_aBone Marrow Transplantation _ximmunology |
| 650 | 0 | 4 |
_aCyclophosphamide _xpharmacology |
| 650 | 0 | 4 |
_aCytarabine _xpharmacology |
| 650 | 0 | 4 |
_aGraft vs Host Disease _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xpharmacology |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xtherapy |
| 650 | 0 | 4 |
_aMitobronitol _xpharmacology |
| 650 | 0 | 4 |
_aTransplantation Chimera _xdrug effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBátai, A | |
| 700 | 1 | _aKelemen, E | |
| 700 | 1 | _aLengyel, L | |
| 700 | 1 | _aReményi, P | |
| 700 | 1 | _aSipos, A | |
| 700 | 1 | _aTorbágyi, E | |
| 700 | 1 | _aAvalos, M | |
| 700 | 1 | _aFekete, E | |
| 700 | 1 | _aFöldi, J | |
| 700 | 1 | _aPáldi-Haris, P | |
| 700 | 1 | _aTamáska, J | |
| 700 | 1 | _aGyódi, E | |
| 700 | 1 | _aRajczy, K | |
| 700 | 1 | _aHoffer, I | |
| 700 | 1 | _aJakab, J | |
| 700 | 1 | _aPetrányi, G G | |
| 700 | 1 | _aPálóczi, K | |
| 773 | 0 |
_tHuman immunology _gvol. 61 _gno. 2 _gp. 101-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0198-8859(99)00143-3 _zAvailable from publisher's website |
| 999 |
_c10671677 _d10671677 |
||